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Role of inflammation in the pathophysiology 
of bronchial asthma 
Airway inflammation is a characteristic feature of 
asthma. It contributes significantly to many features 
of this disease, including airflow obstruction, 
bronchial hyperresponsiveness, and the initiation of 
the injury-repair process (remodeling) found in 
some patients1. 
The inflammation that occurs in asthma can be 
broken-down into 3 stages. First, the acute response 
(edema, smooth muscle contraction and increased 
mucus production) which is completed within a few 
hours. Second, a residual stimulus leads to the 
chronic phase (epithelial cells denudation and the 
influx of inflammatory cells into the airway). 
Finally, chronic airway remodeling (irreversible 
structural changes and progressive loss of 
pulmonary function)2. The mechanism that initiates 
airway inflammation is shown in figure (1). 
 
 
GM-CSF = granulocyte macrophage-colony stimulating factor; ICAM = 
Intercellular adhesion molecule; VCAM = vascular cell adhesion molecule; 
MCP = Monocyte chemoatractant protein; MIP = monocyte inhibitory 
protein. 
 
Figure 1. The mechanism that initiates airway inflammation in bronchial asthma. In sensitized individuals antigen 
interaction with mast cell-bound, specific-IgE antibody results in release of preformed (histamine) and generated (leukotrienes) 
mediators along with cytokines [inteleukins-4 and –5 and GM-CSF]. These various compounds can induce localized inflammatory 
cell influx and activation through the upregulation of various chemokines and adhesion molecules and recruitment of bone marrow 
cells (e.g., eosinophils). Quoted from Lemanske and Busse (2003)1. 
 
Tests for assessing airway inflammatory 
markers of bronchial asthma 
Ideally, a test for airway inflammation should be 
non-invasive, safe, simple to perform, inexpensive 
and should correlate with both indices of 
inflammation obtained using the gold standard tests 
(bronchoalveolar lavage “BAL” and bronchial 
biopsy), and other measures such as pulmonary 
function, disease severity and bronchial reactivity3. 
It is now possible to measure airway 
inflammation using non-invasive tests as induced 




testing e.g. nitric oxide and volatile molecules in 
the liquid phase of breath “breath condensate” and 
even urinary measurements4. Sputum markers tend 
to be more sensitive than blood when assessing 
airway inflammation5. 
 
Inflammatory markers for bronchial asthma 
No single parameter can accurately classify all 
individuals. Assessment of multiple parameters is 
necessary to categorize asthma clinical status 
accurately6. Inflammatory markers for bronchial 
asthma include: 
I. Inflammatory cells 
II. Cytokines and chemokines 
III. Lipid inflammatory mediators 
IV. Immunoglobulins (E, D) 
V. Anaphylatoxic complement C3a, C5a  
VI. Oxidants (including markers of exhaled 
breath) and antioxidants 
VII. Adhesion molecules 
VIII. Neurotrophins and neuropeptides 
IX. Endothelins 
X. Angiogenic and antiangiogenic factors 
XI. Matrix metalloproteinases 
XII. Activated protein C and plasmin system 
 
I) Inflammatory cells 
Eosinophils (number, granular proteins and 
apoptotic markers): 
Eosinophilia in peripheral circulation and airways is 
a characteristic feature of asthma7. Hypodense 
eosinophils (eosinophils with lower density and 
greater number of immunoglobulin receptors) better 
reflect the severity of asthma than the mere count of 
peripheral blood eosinophils as they are 
metabolically more active and proinflammatory 
than the normodense eosinophils8. There is a high 
risk of exacerbation in subjects with blood 
eosinophilic count > 400/cubic mm9. 
Eosinophil cationic protein (one of the 
eosinophil granular proteins) released upon 
eosinophil activation has an essential role in the 
pathogenesis of airway hyperresponsiveness due to 
its cytotoxic effect on airway epithelial cells. It was 
detected in bronchial biopsy specimens and 
elevated in BAL, sputum and peripheral blood 
specimens10. 
Of the 4 basic eosinophil granule proteins, 
eosinophilic protein X (EXP) is the only one that 
can be accurately measured in the urine. It has been 
shown to correlate well with eosinophil activation 
and serum eosinophilic cationic protein level. 
Urinary EXP level reflects the presence of atopy 
and might be useful for monitoring the progression 
of allergic disease11. 
Recently, El-Gamal et al.12 reported 
overexpression of sputum eosinophils and Bcl-2+ 
(antiapoptotic marker) eosinophil percentages in 
asthmatic patients with acute exacerbation than 
controls and demonstrated a positive correlation to 
disease severity. 
T lymphocytes: 
Numerous studies have documented elevated 
numbers of T cells within BAL fluid and within the 
epithelium and submucosa of asthmatic patients13. 
Numerous studies reported increased expression of 
T-helper cell activation markers as CD45RA, 
CD45RO, CD45RA+RO+ and CD25 in peripheral 
blood mononuclear cells of children with atopic 
asthma14 as well as CD80 and CD8615. 
Basophils: 
Blood basophil counts are often increased in 
asthmatic patients. Basophils have been also 
reported in sputum16 and bronchial biopsy 
specimens17. Interestingly, basophils of asthmatic 
children showed increased spontaneous release of 
LTC4 during exacerbation and persisted even after 
subsidence of the attacks suggesting an in vivo 
activation state of basophils18. 
Platelets: 
Platelet factor 4 and B-thromboglobulin are 
sensitive indices of platelet activation. They are 
closely related to clinical improvement, severity 
and response to therapy in asthmatic children19. 
Mast cells: 
Increased number of mast cells has been described 
in the bronchial epithelium using electron 
microscopy and BAL of allergic patients with 
asthma. Increased concentration of tryptase (a 
marker of mast cell degranulation) has been found 
in BAL of asthmatics20. 
 
II) Cytokines and chemokines (figure 2) 
The proteins synthesized and secreted by T, B and 
natural killer (NK) cells, with which they interact 
are referred to as cytokines. They are subdivided 
into interleukins, interferons, colony stimulating 
factors and other cytokines21. 
The initial indication for cytokine involvement 
in the pathogenesis of asthma came from studies 
performed in the early 1990s showing that atopic 
asthma was associated with local TH2 cytokine 
expression (IL-3, IL-4, IL-5, and GM-CSF). They 
were upregulated in asthmatic patients relative to 
control subjects and their receptors were identified 
on the surface of inflammatory cells(22). They can 
prolong the survival of the allergic effector cells 
because of delayed apoptosis23. 
Chemokines are a large group of chemotactic 
cytokines that have been divided into four groups, 
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designated CXC, CC, C and CX3C, depending on 
the spacing of conserved cytokines (where X is an 
amino acid). The CXC chemokines mainly target 
neutrophils and lymphocytes whereas the CC 
chemokines target a variety of cell types, including 
macrophages, eosinophils, basophils and dendritic 
cells24. Forty-seven chemokines and 18 chemokine 
receptors have been identified. Many of the 
chemokine receptors can bind more than one ligand 
allowing extensive overlap and redundancy of 
chemokine function25. 
Chemokines, particularly the eotaxin subfamily, 
have emerged as cytokines likely to be important in 
the regulation of allergic inflammation. They have 
an essential role in regulating leucocyte 
recruitment, basophil histamine release, TH1/TH2 
function and tissue remodeling (including fibrosis 
and angiogenesis). Several chemokines appear to 
have potent effects in lung functions such as airway 
hyperresponsiveness26. 
The main stimuli for secretion of chemokines 
are the early signals elicited during innate immune 
responses (e.g. bacterial products, viral infection 
and proinflammatory cytokines such as IL-1 and 
TNF-α)27. Thus, chemokines provide an important 
link between early innate immune responses and 




IL = Interleukin; MIP = macrophage inflammatory 
protein; CCR = CC chemokine receptor; AHR = 
airway hyperresponsiveness. 
 
Figure 2. Chemokine/cytokine interactions in 
asthma (Quoted from Zimmermann et al., 
2003)26. 
 
III) Lipid inflammatory mediators 
The lipid mediators, leukotrienes (LTs), prosta-
glandins and platelet-activating factor, play an 
important role in the complex inflammatory process 
of airways in bronchial asthma29. 
LTC4 and LTD4 are 1000 times more potent 
bronchoconstrictors than histamine. T helper type 2 
cytokines upregulate LTs synthesis. LTs upregulate 
type 2 cytokine expression and decrease type I 
cytokine expression30. A significant increase in 
sputum LTs in children with asthma was 
demonstrated and paralleled the severity of 
asthma31. 
 
IV) Immunoglobulins (Igs) 
IgE: 
For IgE synthesis a complex series of interactions 
and signals between B and T cells is required32. IgE 
levels are often raised in allergic diseases and 
grossly elevated in parasitic infestations. When 
assessing children for presence of atopic disease, a 
raised IgE may aid in the diagnosis33. However, a 
significant number of allergic individuals have 
normal or low IgE concentrations. Indeed, low 
levels of serum IgE may be more useful in 
excluding atopic disease than elevated levels in 
confirming diagnosis, although patients with low 
IgE can have atopy. Increased total IgE levels 
during infancy, with no evidence of parasitic 
infestation, suggests the likelihood of subsequent 
development of atopic diseases23. 
IgD: 
IgD level may be elevated in atopic diseases but 
there is yet no definite explanation for the high 
levels of IgD. Surface IgD was found to protect 
resting B-cells from deletion allowing them to 
initiate an immune reaction to antigens34. 
 
V) Anaphylatoxic complement C3a, C5a 
The complement system is a vital link between 
innate and adaptive immunity. Complement 
anaphylatoxins C3a and C5a are potential effectors 
of the type 1 hypersensitivity reactions. C3a and C5a 
contribute in asthma pathogenesis. Their receptors 
are expressed in airway epithelial cells and smooth 
muscles35,36. 
 
VI) Oxidants and antioxidants 
Many studies suggest that markers of oxidative 
stress (increased exposure to oxidants and/or 
decreased antioxidant capacities) are increased in 
children and adults with asthma, not only in their 
lungs but also in the circulation37. 
Markers in exhaled breath (nitric oxide and 
others) 
Nitric oxide (NO) was originally recognized as an 
environmental pollutant that destroys the ozone 
layer. However, it is now recognized as an 
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important physiological mediator38. The highest NO 
production is from macrophages and airway 
epithelial cells. NO is synthesized by the oxidation 
of L-arginine by NO synthetase enzyme. In the 
lungs, NO acts as a vasodilator, a  non adrenegic 
non-cholinergic neurotransmitter and an important 
mediator in the inflammatory response39. Exhaled 
NO is a non-invasive test that measures airway 
inflammation. It correlates with peripheral blood 
eosinophils and serum ECP40. 
Several other inflammatory biomarkers have 
been identified in exhaled air or breath condensate 
which include; aldehyde, glutathione, carbon 
monoxide, hydrogen peroxide, ethane and other 
volatile and non volatile compounds41. 
 
VII) Adhesion molecules 
Leukocyte / endothelial cell adhesion molecules are 
essential mediators of both immune and 
inflammatory responses. T cell adhesion molecules 
are classified in three families. These are the 
selectins (E-selectin, L-selectin and P-selectin), 
immunoglobulin-like molecules (ICAM-1, ICAM-
2, ICAM-3, VCAM-1, PECAM-1 and MadCAM-1) 
and integrins (CD29/CD49, CD18/CD11 and 
CD61/CD41)42. 
 
VIII) Neurotrophins and neuropeptides 
Neurogenic inflammation may be initiated by 
activation of sensory nerves by inflammatory 
mediators, irritants, allergens and infections43. 
Neurotrophins are a family of peptides that 
promote survival, growth and differentiation of 
neurons. They may also influence the function of 
non-neuronal cell types, including immune cells. 
They include nerve growth factor, brain derived 
neurotrophic factor, neurotrophin 3 and neuro-
trophin 4/544. 
The traditional cellular sources of neurotrophins 
under physiological conditions are primarily nerve-
associated cells such as glial cells, Shwann cells or 
fibroblasts and neurons themselves. In 
inflammatory processes, neurotrophins are also 
produced by a wide range of hematopoietic cells 
including mast cells, macrophages, T cells and 
airway epithelium45. 
Neuropeptides are small amino acid components 
released from sensory nerves and also from 
inflammatory immune cells such as monocytes, 
dendritic cells, eosinophils and mast cells. 
Neuropeptides such as substance P, neurokinin A 
and calcitonin gene-related peptide (CGRP) may 
amplify the inflammatory process through 
increasing plasma exudation, mucus secretion and 
both recruitment and activation of inflammatory 
cells46. 
 
IX) Endothelins (ETs) 
Human endothelin family comprises three 21-amino 
acid peptides. All three ET isopeptides are potent 
contractile agonists of human airway. ETs are 
synthesized by endothelial and epithelial cells and 
act in a paracrine fashion on nearby smooth muscle 
or connective tissue47. 
 
X) Angiogenic and antiangiogenic factors 
Angiogenesis is regulated by a balance of 
angiogenic and antiangiogenic factors. Induced 
sputum from asthmatic subjects revealed imbalance 
between vascular endothelial growth factor 
“VEGF” (angiogenic factor) and endostatin 
(antiangiogenic factor) levels48. Angiogenesis is an 
essential component identified in airway 
remodeling of bronchial asthma1. 
 
XI) Matirx metalloproteinases (MMPs) 
Matrix metalloproteinases are markers of 
extracellular matrix (ECM) degradation. MMP-2 
and MMP-9 have been suggested to be the major 
proteolytic enzymes to induce airway inflammation 
and remodeling in asthma. Their levels are 
increased in asthmatic patients. Anti MMP therapy 
could be theoretically useful to prevent airway 
remodeling in asthma49. 
 
XII) Activated protein C and plasmin system 
Activated protein C may protect the lung from 
fibrosis and airway remodeling by suppressing 
activation of coagulation, decreasing the secretion 
of inflammatory cytokines and platelet-derived 
growth factor, and promoting fibrinolysis. Low 
activated protein C activity has been observed in 
BAL of asthmatic patients50. 
Plasmin system plays an active role in tissue 
remodeling; plasmin degrades ECM, either directly 
or by activating MMPs. Plasmin system 
components are synthesized by airway cells. 
Inflammatory mediators affect their expression 
which is increased in bronchial asthma51. 
 
Clinical usefulness of inflammatory markers 
in diagnosis and treatment of bronchial 
asthma 
Assessing airway inflammation is important for 
investigating the underlying mechanism, 
diagnosing, monitoring and treating asthma52. 
Evidence of airway inflammation (for example a 
raised exhaled NO or sputum eosinophilia) in 
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asymptomatic child may be indicative of failure to 
take their medications53.  
In trials of corticosteroid withdrawal, increase of 
sputum eosinophils preceded worsening of 
symptoms, deterioration of lung function and 
bronchial hyperresponsiveness. Increases in sputum 
eosinophils have also been associated with 
exacerbations of asthma54. Maintenance of sputum 
eosinophil count less than or equal to 3% is 
associated with few exacerbations, admissions and 
courses of oral steroids55. 
Treatment applications in asthma are based 
upon disease severity. Since asthma is a chronic 
disease whose severity may change over time, it is 
important to adjust treatment to appropriately 
match treatment requirements with disease 
severity. Failure to do this leads to undertreatment 
with the associated risk of impaired quality of life 
and severe exacerbations. Alternatively, over-
treatment may occur, with the risk of excessive 
adverse effects56.  
At present, in patients with asthma, symptoms 
and lung function are used to monitor severity and 
adjust treatment. These measures are imperfectly 
correlated with the underlying pathophysiological 
processes in asthma, namely airway hyper-
responsiveness and airway inflammation. Using 
objective measures of airway hyperresponsiveness 
and airway inflammation may lead to better 
management of asthma57. (Table 1). 
 
The dream is that every patient with bronchial 
asthma could be characterized with respect to the 
profile of involving cells and mediators. Such 
information would provide us with a unique 
understanding of the underlying mechanisms of 
development of disease symptoms and the 
possibility of treating them58. Also, this may help 
in the development of new therapeutic strategies 
such as decreasing cytokine synthesis or release, 
blocking their effects by antibodies or soluble 
receptors as well as administration of anti-
inflammatory cytokines which will undoubtedly 
constitute a breakthrough in the management of 
asthmatic patients59. (Figure 3). 
 
 
Table 1. Inflammatory markers used more commonly to assess response to treatment in bronchial asthma. 
 
0BMarker Comments 
Bronchial biopsies Cellular infiltration 
cytokine/TH expression 
Remodeling changes 
Highly invasive method; direct assessment of 
inflammation in the target organ. 
Skin and nasal biopsies Cellular infiltration 
cytokine/TH expression 
Alternative, less invasive methods to assess responses to 
systemic treatment. 
BALF Cell differential (EOS) 
ECP, cytokines 
Invasive method. Cellular components well documented; 
difficulties with markers in the fluid component due to 
dilution factors. 
Induced sputum Cell differential (EOS) 
ECP, cytokines 
Correlates well with biopsies and BALF data. Widely used 
in research but time-consuming. 
Exhaled air NO Limited to steroid-naïve asthmatics, detected in atopic 
patients only. 
EBC CO, ethane, pentane Not well documented as markers to assess treatment 
response 
 pH, H2O2 and cytokines Simple non-invasive procedures. pH seems to be the only 
rapid marker, whereas measuring others is still time-
consuming. Repeatability, stability and use in monitoring 
is not well documented for all markers. 
Blood Eosinophils 
 
Easy to measure, but reflect changes away from the target 
organ 
 ECP, cytokines ECP is the best eosinophil-derived marker. It correlates 
well with eosinophil activity in the airways. 
Urine EPX Alternative for serum ECP; valuable tool in pediatric 
asthma. 
 LTE4, PGE2 Assess the therapeutic effect of 5-lipoxygenase inhibitors, 
however, leukotriene levels do not respond to steroid 
treatment. 
BALF = bronchoalveolar lavage fluid; ECP = eosinophil cationic protein; NO = nitric oxide; EBC = expired breath 
condensate; EPX = eosinophil peroxidase; LTE4 = leukotriene E4; PGF2 = prostaglandin F2, H2O2 = hydrogen peroxide, CO = 
carbon monoxide.  






APC = antigen presenting cell; Eos = eosinophil; IL= interleukin; IFN-γ = interferon gamma; 
TNF-β = tumour necrosis factor beta. 
 
Figure 3. Important steps in the development of TH2-lymphocytes and potential sites for 
intervention and treatment of bronchial asthma. (Quoted from Colavita et al, 2000)60. 
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